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Many mutations confer upon copper/zinc superoxide dismutase-1 (SOD1) one or more toxic
function(s) that impair motor neuron viability and cause familial amyotrophic lateral sclerosis
(FALS). Using a conformation-specific antibody that detects misfolded SOD1 (C4F6), we
demonstrate that oxidized WT-SOD1 and mutant-SOD1 share a conformational epitope that is not
present in normal WT-SOD1. In a subset of human sporadic ALS (SALS) cases, motor neurons in
the lumbosacral spinal cord displayed striking C4F6 immunoreactivity, denoting the presence of
aberrant WT-SOD1 species. Recombinant, oxidized WT-SOD1 and WT-SOD1 immunopurified
from SALS tissues inhibited kinesin-based fast axonal transport in a manner similar to FALSlinked mutant SOD1. Studies here suggest that WT-SOD1 can be pathogenic in SALS and
identifies an SOD1-dependent pathogenic mechanism common to FALS and SALS.
Amyotrophic lateral sclerosis (ALS) is an adult-onset, motor neuron disease that causes
progressive degeneration of motor neurons and death within 3-5 years of diagnosis 1. The
most prevalent factors associated with inherited forms of ALS (FALS) are mutations in the
SOD1 gene that encodes cytosolic Cu/Zn superoxide dismutase 2. In FALS, cytotoxicity of
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motor neurons appears to result from a gain of toxic SOD1 function, rather than loss of
dismutase activity 3. While the exact molecular mechanisms underlying mutant-SOD1mediated motor neuron degeneration are unclear, prevailing hypotheses suggest a role for
mutation-induced conformational changes that lead to SOD1 misfolding and subsequent
aggregation 4-9.
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The etiology of sporadic ALS (SALS), which accounts for ~90% of ALS, is largely
unknown. In contrast, several genetic variants have been identified in association with FALS
2. That FALS and SALS are clinically and neuropathologically similar implies that the
pathogenesis of these diseases must converge on a common pathogenic pathway and/or
involve similar toxic factors, but such factors have remained elusive 1, 10. WT-SOD1 has
been proposed as a potential link between SALS and FALS 11, 12, although the existence of
a toxic WT-SOD1 species that is associated with SALS in vivo and that recapitulates the
pathogenic features of mutant-SOD1 has not been demonstrated. One hypothesis states that
defects in the normal post-translational modifications of WT-SOD1 or the introduction of
aberrant covalent modifications to WT-SOD1 could induce conformational changes in WTSOD1 that mimic structural features of FALS SOD1 mutants 13-15. Several lines of evidence
support this view, including the reports that metal-depleted 16, 17 and oxidized 11, 18 WTSOD1 exhibit enhanced propensities to misfold in vitro 19, and are toxic when exogenously
administered to cells 11, 17. These observations suggest that aberrantly modified WT-SOD1
and FALS-linked SOD1 mutants share similar structural features; however, common
pathogenic mechanisms triggered by FALS and SALS-related SOD1 species remain elusive.
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Recently, a monoclonal antibody (mab C4F6) was generated against the FALS-linked SOD1
G93A mutant protein and shown to bind preferentially to several FALS-linked SOD1
mutant proteins, as compared to WT-SOD1 20. Thus, the reactivity of C4F6 appears to be
specific for a particular conformation inherent in misfolded SOD1. If aberrant modifications
to WT-SOD1 induce the protein to adopt a mutant-like conformation, we speculated that the
C4F6 antibody could detect misfolded WT-SOD1 species associated with SALS. Moreover,
if WT-SOD1 plays a pathogenic role in SALS, we expected these aberrant WT-SOD1
species to recapitulate one or more toxic effect(s) of FALS-linked SOD1 mutants. Here, we
report investigations of SALS-associated WT-SOD1 species using the C4F6 antibody in
vitro and in vivo. Our recent finding that FALS-linked, mutant SOD1 protein inhibits fast
axonal transport (FAT) (Gerardo Morfini and Scott Brady, submitted and 10) led us to
investigate potential toxic properties of WT-SOD1 that has undergone misfolding in
association with SALS using the same experimental model 21. Our findings demonstrate that
the SOD1 protein can become pathogenic via non-heritable modifications (e.g., oxidation),
thus supporting the hypothesis that conformational abnormalities in WT-SOD1 can underlie
SALS pathogenesis. In addition, functional experiments in isolated squid axoplasm showed
that misfolded WT-SOD1 species inhibit conventional kinesin-based fast axonal transport
(FAT) through a mechanism involving p38 kinase activation. These results provide evidence
for a novel SOD1-dependent pathogenic mechanism that impairs axonal transport in both
FALS and SALS.

RESULTS
Oxidized and mutant SOD1 are conformationally similar
The misfolded-SOD1 conformation-specific C4F6 monoclonal antibody, generated against
the apo-SOD1 G93A antigen 20, 22, reacts with multiple FALS-linked mutant SOD1, but not
WT-SOD1 proteins 20. When normal post-translational modifications of WT-SOD1 are
altered or when new modifications (i.e., oxidation) are introduced, WT-SOD1 acquires some
of the properties observed for FALS-linked SOD1 mutants, such as an enhanced propensity
to misfold 11, 16-18. Based on these observations, we hypothesized that C4F6 may recognize
Nat Neurosci. Author manuscript; available in PMC 2011 May 1.
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aberrantly modified forms of WT-SOD1, and could thus be used as a tool to investigate the
association of such species with SALS in vivo.
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To test this hypothesis, WT-SOD1 was exposed to hydrogen peroxide (H2O2) to generate an
oxidized form of WT-SOD1 (SOD1ox). Fourier-transform mass spectrometry (FT-MS) was
employed to confirm the oxidation of WT-SOD1, as indicated by an increase of 48 Da for
the predominant species in the spectrum of SOD1ox (monoisotopic mass of 15,892 Da; Fig.
1b) compared to unmodified WT-SOD1 (15,844 Da; Fig. 1a). SOD1ox was subjected to
electron capture dissociation (ECD), which confirmed that the sulfhydryl group of Cys 111
encoded within exon 4 (Fig. 2) is fully and irreversibly oxidized to sulfonic acid 23 through
the incorporation of 3 oxygens (Fig. 1c and Supplementary Table 1). No other oxidated
forms of WT-SOD1 were observed.
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A native Western immunoblot analysis revealed that the reactivity of C4F6 is selective for
recombinant SOD1ox, as compared to untreated WT-SOD1 protein. The commercial
monoclonal SDG6 antibody, which is reactive for the native form of SOD1, recognized both
SOD1ox and WT-SOD1 (Fig. 3a). SOD1ox migrated as a relatively diffuse band, indicative
of a heterogeneous population of SOD1 molecules that migrate with both slower and faster
motilities relative to untreated WT-SOD 24. The migration patterns of SOD1ox may be
attributed to a loss of hydrodynamic volume due to misfolding (slower mobility), loss or
exchange of metals (faster mobility), and/or a shift in the monomer-dimer equilibrium
towards the monomer (faster mobility) 25. As expected, C4F6 was reactive with mutant
SOD1 G93A but not WT-SOD1 by a native Western analysis of tissue lysates derived from
the respective transgenic mice (Fig. 3b). C4F6 retained its reactivity towards SOD1 G93A
under denaturing conditions; however, this monoclonal antibody was no longer reactive for
SODox when this protein was denatured (Fig. 3c).
To address whether oxidation of Cys111 is necessary for detection by the C4F6 antibody
under native conditions, we performed the native Western analysis described above for WTSOD1 with the ‘AS-SOD1’ mutant containing the C6A/C111S point-mutations 26. In
contrast to WT-SOD1, there was no evidence of AS-SOD1 oxidation as a result of H2O2
treatment, nor was C4F6 reactive for H2O2 treated AS-SOD1 (Supplementary Figure 1).
Therefore, oxidation of Cys111 is required for the observed reactivity of C4F6 for SOD1ox.
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The C4F6 reactive epitope, which is present in both SOD1 G93A and SOD1ox, was further
investigated in an epitope mapping analysis. GST-tagged constructs encoding either the fulllength SOD1 G93A gene or the SOD1 G93A gene lacking one of the five SOD1 exons were
transfected into HEK-293 cells, and the respective cell lysates were subjected to a Western
blot analysis using C4F6. The immunoblots in Figure 3e show that C4F6 reactivity requires
the presence of exon 4 in GST-SOD1 G93A, which harbors the G93→A mutation (Fig. 2).
As expected, C4F6 was not reactive towards HEK-293 endogenous WT-SOD1, whereas a
commercial anti-SOD1 polyclonal antibody was reactive towards all SOD1 proteins (Fig.
3e).
That C4F6 only recognizes SOD1ox in the native conformation indicates that there is a
conformational epitope within SODox, rather than the sulfonic moiety at Cys111, that is
recognized by C4F6. Moreover, C4F6 is reactive for other FALS-linked SOD1 proteins in
addition to SOD1 G93A under native conditions 20, and yet this antibody only detected
SOD1 G93A but not SOD1 G93C, G93D, G93R, G93S G93V under denaturing conditions
(Fig. 3d). Collectively, these data indicate that C4F6 recognizes an epitope within SOD1
G93A that contains both a conformational component and the G93A sequence component.
The formation of this conformational epitope is induced by both the G93→A mutation and
the Cys111 sulfonic acid moiety (Fig. 3), both of which are within exon 4 (Fig. 2). However,
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the conformational component of the epitope is lost when the SOD1 proteins are denatured,
leaving only the G93A sequence element of the epitope to confer C4F6 reactivity (Figs. 3c
and e).
SOD1ox inhibits kinesin-based fast axonal transport

NIH-PA Author Manuscript

Immunochemical analysis of WT-SOD1, SOD1ox, and FALS-related SOD1 mutants with
the C4F6 antibody suggested a common conformational change shared by FALS-related
SOD1 mutants and SOD1ox. These observations prompted us to compare the effects of
SOD1ox with FALS-linked SOD1 mutant proteins in an ALS relevant biological assay.
Results from vesicle motility assays in isolated squid axoplasm indicated that the FALSlinked SOD1 H46R mutant selectively inhibited conventional kinesin-based fast axonal
transport (FAT) in the anterograde direction (Fig. 4a), whereas the WT-SOD1 protein did
not affect FAT in either the anterograde or retrograde directions (Fig. 4b; Gerardo Morfini
and Scott Brady, submitted and 10). This experimental system allows for quantitative
analysis of membrane-bound organelles (MBOs) moving in both anterograde (conventional
kinesin-dependent) and retrograde (cytoplasmic dynein-dependent) directions 27, 28. Further,
the lack of plasma membrane in this preparation facilitates direct evaluation of the effects of
neuropathogenic proteins on FAT 29, 30. Isolation of the squid axoplasm from the cell body
and removal of plasma membrane allows one to investigate the effect of small molecules
and proteins on FAT in a transcription-independent manner. Next, SOD1ox (5 μM) was
perfused into isolated axoplasm and found to selectively inhibited anterograde FAT (Fig. 4c)
to a similar extent as the SOD1 H46R mutant. Thus, SOD1ox mimics the toxic effect of the
FALS-linked SOD1 mutant in these assays.
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Phosphorylation of the molecular motor conventional kinesin is known to regulate FAT in
vivo 10. Further, FALS-linked mutant SOD1 inhibits FAT by a mechanism involving the
activation of a kinase pathway (Gerardo Morfini and Scott Brady, submitted and 10). To
evaluate the possibility that SOD1ox-mediated inhibition of anterograde FAT similarly
involves the activation of axonal kinases, we screened for changes in the activity of various
protein kinases in axoplasms perfused with either WT-SOD1 or SOD1ox by immunoblotting
with activation-specific phosphoantibodies. No changes in the activities of GSK3 and ERK
were observed between WT-SOD1 and SOD1ox-perfused axoplasms (Fig. 5a, b). In
contrast, antibodies against phosphorylated, catalytically active p38 (pp38) revealed a
dramatic increase in p38 activation in axoplasms perfused with SOD1ox, by comparison
with those perfused with WT-SOD1 (Fig. 5a). Quantitative analysis of immunoblots
indicated that SOD1ox induced an approximately 4-fold increase in p38 activation,
compared to WT-SOD1 (n=6; P<0.05, Fig. 5b). Consistent with these data, co-perfusion of
the highly specific p38 MAPK inhibitors SB203580 31 (5μM; Fig. 5c) or MW01-2-069SRM
32 (10μM; Fig. 5d) with SOD1ox prevented the inhibitory effect of SOD1ox on anterograde
FAT. Thus, inhibition of anterograde FAT by SOD1ox requires activation of p38 kinase.
Taken together, these data indicate that an aberrantly modified form of WT-SOD1, which
share conformational motifs with FALS-linked SOD1 mutant proteins, inhibit conventional
kinesin-based FAT through a mechanism involving p38 activation.
Misfolded SOD1 is present in SALS spinal cord tissues
To address the hypothesis that aberrantly modified forms of WT-SOD1 are associated with
SALS in vivo, we performed immunohistochemistry on post-mortem human spinal cord
(SpC) using the conformation-specific C4F6 antibody that reacts specifically with mutant
SOD1 and SOD1ox but not unmodified WT-SOD1. The clinical and demographic
information for the SALS and control cases analyzed in this study are shown in
Supplementary Tables 2 and 3. In contrast to other studies that employ misfolded-SOD1
conformation-specific antibodies 33, 34, antigen retrieval approaches that can potentially
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alter the antigen conformation were avoided here (see Methods). Positive C4F6 staining was
observed in 4/9 SALS cases (SALS1 to 4, Fig. 6a, d-f). Of the five remaining SALS cases,
the SpC sections from two showed extensive degeneration in the motor regions to the extent
that motor neurons could not be detected. Since motor neurons appear positively stained
with C4F6 (Figs 6a, d-f), we cannot exclude the possibility that these two aforementioned
cases lacking detectable motor neurons would have been C4F6-positive at an earlier stage of
disease. Remarkably, no C4F6 staining was observed in 17 control cases (representative
cases are shown in Fig. 6g and h) (P=0.008, two-tailed Fisher's exact test). Lack of C4F6
immunoreactivity in a FALS case without SOD1 mutations confirmed the specificity of
staining (Fig. 6i). We note that the optimal IHC staining results were obtained with paraffinfixed tissue, whereas IHC of frozen tissue specimens generally did not reveal strong,
positive C4F6 staining (see Methods).
The SOD1 mutant-specific A9G3 monoclonal antibody (Jean-Pierre Julien, unpublished
data), which was also generated against SOD1 G93A 22 but epitope maps to regions
encoded by exons 1 and 2 (Bosco, unpublished data), was not reactive for WT-SOD1 in the
SALS1 case (Fig. 6c). Thus, the WT-SOD1 present in our C4F6-positive SALS cases
exposes a specific epitope that is not detectable by all misfolded-SOD1 conformationspecific antibodies, consistent with other reports of misfolded-SOD1 conformation-specific
antibodies that epitope map outside the region encoded by exon 4 33, 34.
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Aggregated WT-SOD1 is immunohistochemically detected within the Lewy body-like
hyaline inclusions of some 35, 36, but not all 37, SALS cases. To assess the levels of
aggregated WT-SOD1 in our C4F6-positive SALS cases (SALS1-4), we performed an
extraction of insoluble SOD1 from our tissue lysates derived from frozen, post-mortem
human SpC tissue. The protocol was first validated with tissue lysates derived from
transgenic G93A and naïve mice. As expected, immunoblot analysis detected insoluble
SOD1 in the tissue lysates of SOD1 G93A mice 4, but not naïve mice (Supplementary Fig.
2). The levels of insoluble SOD1 extracted from human tissues were not significantly
different between human ALS cases and controls (Supplementary Fig. 2). The diffuse
staining patterns of C4F6 and pan polyclonal anti-SOD1 antibody (Supplementary Fig. 3)
observed in SALS cases, together with the lack of evidence for elevated levels of insoluble
WT-SOD1, suggested that the misfolded WT-SOD1 species in SALS1-4 cases are relatively
soluble. However we cannot exclude the possibility that smaller oligomeric aggregates may
be present, or that SOD1 aggregates could be detected with other anti-SOD1 antibodies that
reportedly detect such species 33, 38.
SALS-derived, misfolded WT-SOD1 mimics mutant SOD1
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The IHC analysis described above suggested that misfolded, C4F6-positive WT-SOD1 is
significantly associated with many SALS cases. We evaluated the possibility that
endogenous misfolded WT-SOD1 from SpC tissue inhibits FAT as observed with SOD1ox
(Fig. 4c), To this end, WT-SOD1 was immunopurified from both SALS and control SpC
tissues under detergent-free conditions (Methods) and perfused in isolated squid axoplasm.
Mass spectrometry confirmed that the purified SOD1 preparations were 99% free of
contaminating proteins. Perfusion of WT-SOD1 (1 μM) immunopurified from SALS tissues
selectively inhibited anterograde, but not retrograde FAT, a pattern of FAT inhibition
consistent with that induced by both FALS-linked mutant SOD1 (Fig. 4a; Gerardo Morfini
and Scott Brady, submitted and 10) and SOD1ox (Fig. 4c). By contrast, WT-SOD1
immunopurified from control tissues had no effect on FAT (Fig. 7b). Co-perfusion of the
conformation specific C4F6 monoclonal antibody (22.5 ng) blocked the inhibitory effect of
SALS-derived SOD1 (Fig. 7c), demonstrating that C4F6-reactive SOD1 species mediate the
inhibitory effect on FAT. Results shown in Figure 7 are representative of 3-5 independent
squid axoplasm assays, each performed with human-derived WT-SOD1 proteins from two
Nat Neurosci. Author manuscript; available in PMC 2011 May 1.
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separate immunopurification preparations (SALS1, 2 and 4, and control 6). The fact that
mild, detergent-free conditions (Methods) were employed to immunopurify WT-SOD1
proteins from human SpC lysates further suggested that the toxic, SALS-derived WT-SOD1
species are relatively soluble.

DISCUSSION
Approximately 150 mutations dispersed throughout the SOD1 sequence have been linked to
FALS (http://alsod.iop.kcl.ac.uk/). In many cases, these represent subtle, conservative (e.g.
Gly→Ala) amino acid substitutions 3; nonetheless, all these mutations lead to an ALS
phenotype. While pathogenic mechanisms underlying FALS-linked SOD1-mediated toxicity
have not been definitively elucidated, a prevailing hypothesis is that FALS-linked mutations
induce an altered or misfolded conformation in SOD1 4, 5, 7-9 that modifies its interactions
with other proteins and perturbs its cellular localization 39-41.
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Given the common pathological effects of diverse FALS-linked SOD1 mutations, it seems
plausible that alterations to the non-Mendelian, post-translational modifications of SOD1
may similarly lead to an ALS phenotype 13-15. For example, disruptions of the normal
SOD1 post-translational modifications (Fig. 2), such as subunit dimerization, the
intrasubunit disulfide bond between residues Cys57 and Cys146, and the coordination of
copper and zinc, have all been shown to cause WT-SOD1 to aggregate 16, 17, 25, 38, 42.
Moreover, aberrant post-translational modifications of SOD1, such as oxidation, have
adverse effects on WT-SOD1 protein conformation 11, 15, 18. By employing the C4F6
monoclonal antibody 20, we found that both oxidation of Cys111 (Fig.1) and mutagenesis of
G93→A induce the formation of a conformational epitope that includes elements of exon 4
(Fig. 2) and that is not normally exposed by WT-SOD1 (Fig. 3). In addition to this
conformational component of the C4F6 epitope that is shared by SOD1ox and SOD1 G93A,
there is an aminoacid sequence component that includes G93A, which could be expected
based on the fact that the SOD1 G93A antigen was used to raise the C4F6 antibody 20, and
which likely explains the stronger reactivity of C4F6 for G93A relative to SOD1ox under
native conditions (Supplementary Fig. 1). Under denaturing conditions, the conformational
epitope is lost and only the G93A sequence element remains to confer reactivity with C4F6,
thus explaining a lack of C4F6 reactivity for SODox and other G93 variants under
denaturing conditions (Figs. 3c and e).
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Studies of human spinal cord tissues with C4F6 revealed the presence of aberrantly folded
WT-SOD1 species in approximately half of the available SALS cases, but not in control
cases (Fig. 6). These results indicate that at least a subset of SALS cases contain WT-SOD1
proteins that are structurally similar to FALS-linked SOD1 mutant proteins. The lack of
C4F6 reactivity in the remaining SALS cases may indicate that misfolded SOD1 is not
associated with ALS pathogenesis for these cases, suggesting that modified WT-SOD1 plays
a role in a subset of SALS in an analogous manner to the role that mutant-SOD1 plays in a
subset of FALS. However, we cannot confirm that the C4F6 antibody is reactive for all
possible misfolded forms of WT-SOD1.
Our finding that misfolded SOD1 is associated with SALS is consistent with the report that
an aberrant 32-kDa, SOD1-containing species is indirectly detected through a biotinylation
cross-linking reaction with homogenized tissue lysates from both SALS and FALS 12. Here,
we probe for a misfolded SOD1 conformation in SALS using an IHC approach on fixed
tissues with C4F6, a conformation-specific monoclonal antibody. Moreover, we demonstrate
that these misfolded WT-SOD1 species derived from C4F6-positive SALS cases
recapitulate the toxic effect of FALS-linked mutant SOD1 on FAT (Fig. 7). Further, we
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show that activation of p38 MAPK is a common feature of both SALS- and FALS-linked
SOD1 inhibition of FAT (Fig. 5 and 10).
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While we have shown that C4F6 is reactive for an oxidized form of WT-SOD1 (Fig. 3a), it
is possible that other modifications to WT-SOD1, including alterations in normal posttranslational modifications 16, 17, 25, 38, might also induce an altered conformation that
confers C4F6 reactivity. That different modifications to SOD1 can induce similar structural
consequences is supported by observations that C4F6 reacts with different FALS-linked
SOD1 mutants 20, and by a recent hydrogen/deuterium exchange study that revealed
enhanced flexibility within the same SOD1 electrostatic loop region (residues 133-144,
located between β-strands 7 and 8; Fig. 2) for a panel of 13 different FALS-linked SOD1
mutants 7. Additional studies with alternate misfolded forms of WT-SOD1 and different
SOD1 conformation specific antibodies will provide greater insight into the conformational
similarities of these proteins and their prevalence in SALS.
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Although the C4F6 antibody recognizes a conformation-dependent epitope common to both
mutant and WT-SOD1 proteins associated with ALS pathology, the critical epitope is not
detected by all antibodies that recognize other misfolded SOD1 species. For example, our
A9G3 antibody detects a subset of FALS-linked mutant SOD1 species, but does not react
with spinal cord sections from SALS patients that are immunoreactive for C4F6 (Fig. 6c).
Similarly, both the SEDI (SOD1 Exposed Dimer Interface) and USOD (Unfolded SOD1)
antibodies failed to detect WT-SOD1 in SALS cases 33, 34. There are several significant
distinctions between the epitopes recognized by C4F6 and the SEDI and USOD antibodies.
C4F6 is reactive for a conformational epitope that includes G93 encoded within exon 4 (Fig.
3), which is distal to those epitopes recognized by SEDI and USOD (Fig. 2). Moreover, both
SEDI and USOD are reactive for linear sequences that can become exposed in aggregated
SOD1 inclusions in FALS cases, whereas the misfolded WT-SOD1 species in our SALS
cases is relatively soluble as evidenced by the diffuse C4F6 staining pattern (Fig. 6), the low
levels of insoluble WT-SOD1 detected in our SALS cases (Supplementary Fig. 2), and the
ability to purify these species under detergent-free conditions while maintaining their
inhibitory effect on anterograde FAT (Fig. 7). Importantly, our IHC methods do not require
the harsh conditions used for antigen-retrieval. Such treatments may disrupt the C4F6-like
conformational-epitope, but enhance the detection of epitopes like those for the SEDI and
USOD antibodies that are otherwise buried 33, 34. Thus, the differing results obtained with
the C4F6, SEDI and USOD antibodies are likely due to the different epitopes recognized by
these antibodies.

NIH-PA Author Manuscript

The foregoing analyses of immunoreactivity patterns for the C4F6 antibody reveal that
genetic variants transmitted as Mendelian traits and non-inherited modifications to SOD1
can both induce similar structural perturbations within the protein, and that non-inherited
modifications of SOD1 can be associated with SALS. A critical question that follows
directly from these observations is whether these SALS-linked modifications confer upon
WT-SOD1 the same toxic properties that are elicited by FALS-linked SOD1 mutations,
including activation of p38 and inhibition of FAT. Both recombinant SOD1ox (Fig. 4c) and
WT-SOD1 derived from C4F6-postive SALS spinal cord tissues (Fig. 7a) recapitulate this
pattern of mutant-SOD1 mediated FAT inhibition, whereas untreated recombinant WTSOD1 and WT-SOD1 derived from control spinal cord tissues had no effect (Figs. 4b and
7b, respectively). The effect of SOD1 from C4F6-postive SALS spinal cord on anterograde
FAT was abolished by incubation with the C4F6 antibody prior to perfusion (Fig. 7c). C4F6
also abolished the ability of FALS mutant SOD1 to inhibit FAT (data not shown).
Biochemical and pharmacological experiments further indicated that the inhibition of
anterograde FAT induced by SOD1ox involved activation of p38 kinase (Fig. 5). FALSlinked mutant SOD1 mediated defects in axonal transport have been reported previously 10,
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and were thought to represent an early pathogenic event in mutant-SOD1 transgenic
mice that contributes to a “dying back” mode of motor neuron degeneration 45, 46, 47. That
the inhibition of FAT is selectively in the anterograde direction demonstrates that this effect
of mutant SOD1 and SOD1ox shows specificity, as this effect is not universally observed for
all toxic, neurodegenerative disease associated proteins 10. The pattern of FAT inhibition is
largely determined by the nature of the regulatory kinases that become activated by the toxic
protein 10. Both modified WT-SOD1 (Fig. 5) and several mutant-SOD1 proteins (Gerardo
Morfini and Scott Brady, submitted and 10) inhibit FAT through a mechanism involving
specific activation of p38 MAPK.
Concurrent studies showed that p38 directly phosphorylates kinesin-1 subunits of
conventional kinesin and dramatically inhibited the translocation of this motor protein along
axonal microtubules, thereby providing a common molecular basis for the effects of
activated p38 kinase activity on anterograde FAT 10 (Morfini and Brady, submitted). Thus,
SALS-associated WT-SOD1 species induce the same defects on conventional kinesin-based
FAT as FALS-linked SOD1 mutants, and by the same molecular mechanism.
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The concept that proteins can become pathogenic via both inheritable and non-heritable
modifications has precedence in the context of other neurodenegerative diseases, as
exemplified by α-synuclein in Parkinson's disease, Aβ or tau in Alzheimer's disease and
frontotemporal dementia (FTDP). Although our data do not rule out potential toxic effects of
aggregated WT-SOD1 species in ALS pathogenesis, they reveal toxic effects associated
with relatively soluble, misfolded WT-SOD1 species in SALS. While aberrantly modified
WT-SOD1 is aggregation-prone in vitro 16, 17, 25, 38, the toxic species in vivo may in fact be
a pre-aggregated, conformationally mis-folded form of the protein.
In conclusion, our investigations indicate that misfolded, SALS-linked WT-SOD1 proteins
activate the same neurotoxic mechanism that is invoked by FALS-linked SOD1 mutants,
strongly suggesting that conformational abnormalities and post-translational modifications
in WT-SOD1 can contribute to SALS pathogenesis. These studies identify a novel
pathogenic mechanism for ALS common to both mutant-SOD1-mediated FALS and many
cases of SALS.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Antibodies and reagents
In our experiments, we used antibodies to SOD1 (PC077, the Binding Site; Calbiochem,
574597; SDG6 clone, Sigma), mutant-SOD1 (C4F6 and A9G3 20), KHC (H2) 30, phosphop38 MAPK (Cell Signaling #9215), phospho-ERK (Santa Cruz #7383), and phospho-GSK3
(Santa Cruz #11757). Secondary antibodies included horseradish peroxidase (HRP)conjugated rabbit anti-sheep IgG (Upstate, 12-342) and HRP-conjugated rabbit anti-Mouse
IgG (Sigma, A9044). SB203580 was obtained from Calbiochem and handled as described
30, and MW01-2-069SRM was a generous gift from (M. Watterson, Northwestern
University. Total protein concentration was determined using bicinchoninic acid (BCA)
assay (Pierce #23225).

Human samples
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Human control and SALS paraffin-embedded spinal cord tissues for IHC analysis, and
frozen tissues for immunopurification of WT-SOD1, were obtained through the
Massachusetts Alzheimer's Disease Research Center (ADRC) at Massachusetts General
Hospital, with the appropriate IRB approval. All experiments were performed with either
lumbar or thoracic SpC tissue sections. All available demographics and clinical information
for the SALS and control cases analyzed throughout this study are in Supplementary Tables
1 and 2.

Immunoblots
Samples for native Western analysis were prepared with 2X loading buffer (Invitrogen,
LC2673), separated by PAGE with 12% Tris-Glycine Gels (Invitrogen, EC60052BOX) in
Tris-Glycine buffer (Invitrogen, LC2672) for 3 hours at 4°C, and transferred to PVDF
(Pierce #88518) in transfer buffer, pH 9.2 (Invitrogen, LC3675) for 90 min at 4°C.
Membranes were fixed for 5 minutes with Ponceau S stain (Sigma # P7170) and blocked for
1 hour at 25°C in 5% nonfat dry-milk (BioRad #170-6404). Blots were probed with either
C4F6 or with SDG6 overnight at 4°C followed by HRP-conjugated rabbit anti-Mouse IgG.
Blots were visualized by chemiluminescence (Pierce #34095). Samples for denaturing
Western analyses were prepared in 4X loading buffer (Invitrogen #NP0007), separated by
SDS-PAGE with 4-12% Bis-Tri gels (Invitrogen) in MES running buffer (Invitrogen
#NP0002), and transferred to PVDF with transfer buffer (Invitrogen #NP0006-1). Unless
otherwise noted, blots were processed as described above for native Westerns.
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Production of recombinant SOD1 proteins
To produce human WT-SOD1 recombinant protein, the detailed protocol for insect cell
expression and subsequent purification described by Hayward et al was employed 49. The
human WT-SOD1 baculovirus stock was a generous gift from Drs. Lawrence Hayward and
Ashutosh Tiwari (University of Massachusetts Medical School). The established protocol
was modified to use TN5B1-4 (High 5) cells from Trichoplusia ni, which were a generous
gift from Drs. Jonathan Francis and Ru-Ju Chain (Massachusetts General Hospital).
Recombinant SOD1ox was prepared by exposing human WT-SOD1 to 10 mM hydrogen
peroxide 11 (Sigma) at room temperature for 16-24 hours, after which the reaction was
quenched by buffer exchanging SOD1ox into PBS using a PD-10 column (GE Healthcare).
SOD1 G93A was prepared as described above for SOD1 WT. SOD1 H46R was a generous
gift from Drs. Lawrence Hayward and Ashutosh Tiwari (University of Massachusetts
Medical School) 49. AS-SOD1 was a generous gift from Dr. Jill Zitzewitz (University of
Nat Neurosci. Author manuscript; available in PMC 2011 May 1.
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Epitope mapping analysis
GST-tagged SOD G93A full-length, and GST-tagged SOD G93A lacking one of the five
exons were cloned into the pcDNA3.1 vector, and transfected into HEK-293T cells
(American Type Culture Collection) with Lipofectamine 2000 (Invitrogen) according to
manufacture's instructions. Cells were then lysed with radio immunoprecipitation assay
(RIPA; Boston BioProducts) buffer supplemented with protease inhibitors (Roche,
11873580001). Extracts from cells expressing SOD1 G93C, G93D, G93R, G93S G93V
mutants 8 were a generous gift from Drs. David Borchelt and Mercedes Prudencio
(University of Florida).

Immunohistochemistry
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Tissues were de-paraffinized through histology grade xylenes (3 times for 5 minutes each)
and a graded alcohol series (100%, 95% and 70% ethanol; 2 times for 2 minutes each). A
method for antigen retrieval (ie acid, heat or proteolysis induced) was avoided when C4F6,
the conformation-specific monoclonal antibody was used. Sections were incubated in 3%
hydrogen peroxide (Sigma), blocked with 10% normal goat serum (Jackson
ImmunoResearch Laboratories, Inc), and incubated with C4F6 (1 μg/mL) prepared in
antibody diluent (Dako, 3022) overnight at 4°C. Sections were incubated with biotinylated
anti-mouse secondary antibody followed by VECTASTAIN RTU ABC reagent according to
the manufacture's instructions (Vector Laboratories, PK-2200). Sections were
colorimetrically developed using the 3, 3'-diaminobenzidine (DAB) substrate kit (SK-4100),
and cover-slipped with paramount.
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For IHC with the pan anti-SOD1 antibody, the following procedure was used. Antigen
retrieval was carried out with 0.01 mol/L citrate buffer at pH 6.0, in an 800-W microwave
oven for 10 minutes, two times before immunostaining. The slides were stained on the
DAKO Autostainer (DAKO Corporation, Carpinteria, CA). The sections were first blocked
for endogenous protein binding and peroxidase activity with an application of Dual
Endogenous Block (DAKO) for 10 minutes, and then with goat serum for 60 minutes. The
sections were then incubated with a sheep polyclonal antibody (Calbiochem, 574597) at
1:100 overnight at 4°C. Sections were then incubated with HRP conjugated with anti-sheepIgG (Upstate, 12-342) at 1:500 for 60 minutes, and treated with diaminobenzidine (DAB)
for 5 minutes. The sections were counterstained with hematoxylin before sealing with
permanent media.

Immunopurification and extraction WT-SOD1 from human tissues
Individual immunopurification columns were prepared by coupling 3.5 mg anti-SOD1
antibody (Binding Site, PC077) to 100 mg cyanogen bromide-activated-Sepharose 4B resin
(Sigma, C9142) according to the manufacture's instructions, and the antibody cross-linked
resin was then transferred into Bio-Spin Columns (BioRad, 732-6008). Frozen SALS and
control, lumbar or thoracic SpC tissue sections (~100 mg) were homogenized (Wheaton,
903475) in lysis buffer (25 mM Tris, pH 7.8 supplemented with protease inhibitors; Roche,
11873580001) at 4°C and cleared by centrifugation at 13k rpm and 4°C. The pellet was
stored at -80°C, and the cleared lysate was applied to an individual immunoaffinity column
(1 unused column per sample), and the flow-through saved on ice. The column was washed
4 times with 600 μL (~20 column volumes total) wash buffer (25 mM Tris, 100 mM NaCl,
pH 7.8), followed by elution of WT-SOD1 proteins with 2 × 500 μL gentle antibody elution
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buffer, pH 6.6 (Pierce, 21027). The columns were re-equilibrated in lysis buffer, the flowthrough re-applied, and the purification repeated for a total of 3 times in order to deplete the
lysate of WT-SOD1. Elutions were buffer exchanged into 25 mM HEPES, pH 7.4 using 10K
MWCO Vivaspin concentrators (Sartorius, VS15RH01), concentrated to ~100 μL with
microcon concentrators (Millipore, 42406). The concentrations of WT-SOD1 proteins were
determined by Western and densitometry (Image J) analyses with recombinant WT-SOD1
standards.
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WT-SOD1 was extracted from the insoluble pellet using a modified protocol of Wang et al
50. Briefly, pellets were re-suspended in 1mL washing buffer (50mM Tris HCL 100mM
NaCl pH 7.4, 10% glycerol, 1% Triton, 0.5% NP-40, protease inhibitor) and centrifuged (10
minutes) at 13000 rpm at 4°C for a total of 4 times. The resulting pellet was re-suspended in
re-solublization buffer (50mM Tris HCL 100mM NaCl pH 7.4, 10% glycerol, 1% Triton,
0.25mM DTT, 1mM EDTA, 2.5% SDS, protease inhibitor), heated to 100°C for 20 minutes,
sonicated (Transsonic 310) for 30 minutes, and heated again before centrifuging at 13krpm
(10 minutes) at room temperature. Five μg total re-solubilized protein was subjected to a
Western analysis with an anti-SOD1 antibody (Calbiochem, #574597) as described above,
except using the secondary anti-sheep IRDye800cw antibody (Rockland, 613-431-002), the
Odyssey Infrared Imager (LiCor, Model 9120) and the Odyssey Software (LiCor, V3.0) for
densitometry analysis. One μg total re-solublized protein and 0.43 μg of the fourth wash
that preceded the re-solubilization was visualized by silver stain analysis (Bio-Rad
Laboratories’ Silver Stain Plus kit, 161-0449) to check the total protein loaded to each well
qualitatively.
The protocol above was used to extract SOD1 from fresh spinal cord tissue isolated from
transgenic SOD1 G93A mice (B6/SJL, the Jackson Laboratory, Bar Harbor, ME) and naïve
mice (C57/BL6, the Jackson Laboratory, Bar Harbor, ME).

Vesicle motility assays in isolated squid axoplasm
Vesicle motility assays and immunoblot analysis of axoplasmic kinases were performed as
described 29, 30.

Mass spectrometry analysis of SOD1 proteins
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Reversed phase liquid chromatography (LC) was performed for WT-SOD1 and SOD1ox
(Fig. 1) using a two-dimensional nanoflowrate LC (Eksigent); 5mm, 300 μm ID guard
column (LC Packings, Part Number 160454); and a self-packed 14cm, 100μm ID column,
with 5 μm beads (taken from a larger Targa column). Buffer A was 0.1% formic acid in
HPLC grade water, Buffer B was 100% HPLC grade acetonitrile. Samples were diluted to a
final formic concentration of 0.1% and injected. Following injection, samples were washed
on the guard column with 160 column volumes of Buffer A (8 μL/min), and eluted at 650
nL/min using a 0-40% gradient over 30 minutes. For intact protein MS/MS, SOD1 was
disulfide reduced in 50mM tris(2-carboxyethyl)phosphine and 0.1mM EDTA, desalted using
C18 ZipTips (Millipore), and infused directly. Samples were introduced via a nanospray ion
source with dual ion funnel (Apollo II) connected to a hybrid quadrupole Fourier transform
ion cyclotron resonance (FT-ICR; FT-MS) mass spectrometer (apex Qe-94, Bruker
Daltonics). The instrument was equipped with a hollow cathode for electron capture
dissociation. External calibration of m/z scale was performed using ES tuning mix (Agilent,
G2431A) using peaks at m/z 622, 922, 1522, and 2122.
After desolvation, the ions were transferred from a source hexapole to the quadrupole mass
filter where isolation could occur in a second hexapole (collision cell). Ions accumulated in
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the second hexapole were then transferred through ion optics region of the instrument to the
ICR cell. Frequency sweep excitation was followed by image charge detection. For ECD
experiment, activation of in the ICR cell was performed using a 105 Vpp, 1000 Hz offresonant, 4 ms sustained off-resonance irradiation (SORI) during ECD pulse. Important
instrument operation parameters include source declustering potential 40V, hexapole 1
accumulation time = 0.1 ms, collision cell accumulation time = 1 s, time of flight = 1.8
milliseconds (D2), sidekick extraction voltages = -1.0 V (EV1, EV2, DEV2), RF excitation
voltage = 130 V, ICR trapping potential 1.2 V, for MS/MS: Q1 m/z = 887.0 (for SOD1ox),
isolation window (m/z) = 5, ECD bias = 6 V, ECD lens = 20 V, ECD duration = 4 ms.
Intact protein masses were reconstructed using the “deconvolution” function from
DataAnalysis (Bruker Daltonics, version 3.4), and monoisotopic masses were determined
using the Snap II algorithm (Bruker Daltonics). MS/MS data was automatically searched in
human protein sequence database (MSDB) using Mascot TD and was matched to human
SOD1 with trioxidation at Cys111.
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For the analysis of AS-SOD1 proteins (Supplementary Fig. 1), samples were diluted in 0.1%
trifluoracetic acid (TFA) to 1μg/μL and 5μL was injected using a 10μl loop injector onto a
μ-precolumn C4 (Vydac) 15mm × 1mm, 3μm, 300Ǻ (LC-Packings) using a flow rate of
50μL/min with 10% acetonitrile (ACN) and 0.1% formic acid (FA). The mass spectra were
acquired on a Q-Tof using W-mode (Waters, Inc.) and the electro spray voltage set to
3500V. During the gradient, from 10% ACN, 0.1% FA to 95% ACN, 0.1% FA over 5
minutes, 3 second scans were collected from m/z 500 – 2000. The spectra under the eluted
peak were summed, and deconvoluted using MaxEnt1 (Waters, Inc).

Statistical analysis
A two-tailed Fisher exact test was used to determine the significance between SALS and
control cases positively stained with the C4F6 antibody (Fig. 6). The activation of kinases in
squid axoplasm and effects of FAT by SOD1ox (Fig. 5b) and insoluble levels of SOD1 in
control and human tissues were tested using a pooled t-test of μ1-μ2 (Datadesk). A P <0.05
was considered statistically significant for all analyses.
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Figure 1. Mass spectrometry confirms the oxidation of WT-SOD1 upon exposure to hydrogen
peroxide (H2O2)

The Fourier-transform mass spectrometry (FT-MS) spectra for (a) untreated WT-SOD1 and
(b) oxidized WT-SOD1 (SOD1ox). Data shown have been automatically deconvoluted and
reconstructed into a mass domain. (a) The conditions under which the FT-MS analysis was
performed reduced the integrity of the SOD1 dimer interface and the SOD1 metal binding
capacity. Therefore, the apo form of WT-SOD1 (15,844 Da – average nominal mass) is the
predominate species in the mass spectrum of unmodified WT-SOD. (a-b) Peaks
representing SOD1 adducts containing sodium, potassium and phosphate ions from the
buffers employed during the purification of SOD1 are indicated. (b) The predominant
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species in the SOD1ox spectrum has a mass increase of 48 Da (15,892 Da) relative to apoSOD1, which corresponds to the incorporation of 3 oxygens (+3ox; +48 Da). (c) SOD1
proteins were subjected to gas-phase isolation followed by electron capture dissociation
(ECD, shown for SOD1ox). MS/MS fragments were assigned using monoisotopic masses
with a 5 ppm cutoff and superimposed upon the SOD1 primary sequence (top), where
indicates unmodified, c-type fragment ions that include the N-terminus, indicates
unmodified z-type fragment ions that include the C-terminus, and indicates +48 Da
modified z-type fragment ions corresponding to the conversion of the sulfhydryl group at
Cys 111 into sulfonic acid (+3ox). Inset shows raw data for c729+ fragment. The SOD1ox
peptides resulting from EDC that were used to deduce the Cys111 site of oxidation are
shown in Supplementary Table 1.
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Figure 2. The structure of WT-SOD1
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The X-ray crystallographic structure of WT-SOD1 (pdb2C9V) 48 modeled in PyMOL. WTSOD1 residues G93 and C111 within exon 2 are highlighted and labeled in purple. The zinc
and copper atoms are shown in light cyan and orange, respectively. SOD1 conformation
specific antibodies epitope map to the following regions: C4F6 to exon 4 (residues H80V118 highlighted in red); A9G3 (Fig. 4c) to exons 1 and 2 (comprised of β-strands 1-4);
SEDI 38 to β-strand 8; and USOD 33 to β-strand 4.
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Figure 3. The C4F6 monoclonal antibody reacts with a conformational epitope shared by
SOD1ox and mutant SOD1
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(a) Recombinant SOD1ox and WT-SOD1 (6 μg/lane) were subjected to a Western analysis
using native (non-denaturing) gels with the C4F6 and SDG6 monoclonal antibodies. Native
SOD1ox, but not WT-SOD1, is detected by C4F6, whereas SDG6 is reactive for both
proteins. The samples were diluted (1 ng/lane) and subjected to an SDS (denaturing)
Western analysis with a polyclonal anti-SOD1 antibody (Binding Site) to demonstrate equal
gel loading. (b) The native Western shows that C4F6 is reactive only for native SOD1
G93A, whereas SDG6 is reactive only for native WT-SOD1 in lysates (30 μg total protein/
lane) that were derived from the respective transgenic mouse. The SDS (denaturing)
Western analysis, performed as in (a), demonstrates equal gel loading. (c) C4F6 is reactive
for recombinant SOD1 G93A (55 ng/ lane), but not SODox (55 ng/ lane), whereas a
polyclonal anti-SOD1 antibody (Calbiochem) detects both proteins. (d) Under denaturing
conditions, C4F6 is reactive only for SOD1 G93A but not the other indicated SOD1
mutants. (e) C4F6 eptitope maps to exon 4. Lysates (30 μg total protein) from HEK 293
mammalian cells transfected with the indicated GST-tagged construct (Δ1-5 denote the
respective exon deleted construct, FL = full length) were probed with C4F6 or a polyclonal
anti-SOD1 antibody (Binding Site).
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Figure 4. SOD1ox recapitulates the inhibitory effect of FALS-linked mutant SOD1 on
anterograde FAT
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Vesicle motility assays in isolated squid axoplasm. Individual fast axonal transport (FAT)
velocity (μm/sec) measurements (arrowheads) are plotted as a function of time (minutes).
Dark arrowheads and line represent anterograde, conventional kinesin-dependent FAT rates.
Grey arrows and line represent retrograde, dynein-dependent FAT rates. (a) Perfusion of 5
μM of the FALS-linked H46R mutant into squid axoplasm caused a marked reduction in the
rate of anterograde FAT (n=4). (b) In contrast to (a), perfusion of 5 μM WT-SOD1 in the
squid axoplasm had no effect on anterograde or retrograde FAT rates (n=4). (c) Perfusion of
5 μM SOD1ox mimicked the inhibitory effect of SOD1 H46R on anterograde FAT (n=4).
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Figure 5. p38 mediates the inhibition of anterograde FAT induced by SOD1ox
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(a) Immunoblotting analysis using activation-specific phosphoantibodies reveals a marked
activation of p38 (p-p38) in axoplasms perfused with recombinant oxidized SOD1
(SOD1ox), compared to those perfused with recombinant unmodified WT-SOD1 (WT). In
contrast, no changes were found in the activities of ERK (pERK) and GSK3 (pGSK3) in
association with a specific SOD1 species. A monoclonal antibody against SOD1 (D3H5) 22
confirmed similar levels of SOD1 perfusion, and antibodies against kinesin-1 (KHC)
provided a loading control for total levels of axoplasmic protein. Results from three
independent experiments are shown (Squid 1-3). (b) Quantitation of results in (a) reveals an
approximately 4-fold increase in the phosphorylation of p38 kinase (indicative of p38
activation) in SOD1ox-perfused axoplasms, compared to unmodified WT-SOD1-perfused
axoplasms (n=6, P<0.05 (*) by the pooled t-test of μ1-μ2). Error bars reflect the standard
error of multiple measurements. Co-perfusion of the highly specific p38 inhibitors
SB203580 (c) and MW01-2-069SRM (d) blocked the inhibitory effect of SOD1ox on
anterograde FAT (compare to Fig. 4c). Similarly, FALS-linked mutant SOD1 polypeptides
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inhibit anterograde FAT through a mechanism involving activation of p38 kinase (Gerardo
Morfini and Scott Brady, submitted and 10).
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Figure 6. The C4F6 monoclonal antibody is reactive for WT-SOD1 in SALS tissues

(a,d,e,f) C4F6 positive staining is shown for 4 SALS cases (SALS1-4). The positive staining
observed for SALS1 (shown in panel a) is lost when C4F6 is excluded from the staining
protocol (b) or when the alternative SOD1-mutant specific A9G3 antibody is employed (c).
Representative control cases (g-h) and an SOD1-negative FALS case (i) illustrate the lack of
positive C4F6 reactivity for such cases. In total, in 4/9 SALS cases exhibited positive C4F6
staining, whereas 0/17 control cases exhibited positive staining. For clinical and
demographic information on these cases, see Supplementary Tables 2 and 3.
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Figure 7. WT-SOD1 purified from SALS tissues inhibits anterograde FAT
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hSOD1 immunopurified from spinal cords of SALS (SALS hSOD1) and control (Ctrl
hSOD1) were perfused into isolated squid axoplasm, and the effects on FAT evaluated as in
Fig. 4. (a) Perfusion of SALS-derived hSOD1 (1 μM) selectively inhibits anterograde FAT
(dark lines, right arrowheads) while retrograde FAT (gray lines, left arrowheads) remains
unchanged (n=5 motility plots, from 2 independent immunopurifications of hSOD1). The
inhibitory effect of SALS-derived hSOD1 on FAT mimics that of FALS-SOD1 H46R and
SOD1ox (Fig. 4). (b) Perfusion of control-derived hSOD1 has no effect on FAT (n=3
motility plots, from 2 independent immunopurifications). (c) Co-perfusion of the C4F6
monoclonal antibody (22.5 ng) with SALS-derived hSOD1 blocked the inhibitory effect of
SOD1 on anterograde FAT (n=3 axoplasms), demonstrating that the C4F6-reactive SOD1
species mediate the inhibitory effect on FAT.
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